DYNE THERAPEUTICS INC (DYN) Fundamental Analysis & Valuation

NASDAQ:DYN • US26818M1080

Current stock price

19 USD
+0.32 (+1.71%)
At close:
19.2 USD
+0.2 (+1.05%)
After Hours:

This DYN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DYN Profitability Analysis

1.1 Basic Checks

  • DYN had negative earnings in the past year.
  • In the past year DYN has reported a negative cash flow from operations.
  • DYN had negative earnings in each of the past 5 years.
  • In the past 5 years DYN always reported negative operating cash flow.
DYN Yearly Net Income VS EBIT VS OCF VS FCFDYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -37.59%, DYN is in line with its industry, outperforming 57.95% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -45.90%, DYN is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
Industry RankSector Rank
ROA -37.59%
ROE -45.9%
ROIC N/A
ROA(3y)-75.48%
ROA(5y)-63.28%
ROE(3y)-118.25%
ROE(5y)-92.38%
ROIC(3y)N/A
ROIC(5y)N/A
DYN Yearly ROA, ROE, ROICDYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DYN Yearly Profit, Operating, Gross MarginsDYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DYN Health Analysis

2.1 Basic Checks

  • DYN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DYN has been increased compared to 5 years ago.
  • Compared to 1 year ago, DYN has a worse debt to assets ratio.
DYN Yearly Shares OutstandingDYN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DYN Yearly Total Debt VS Total AssetsDYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • DYN has an Altman-Z score of 6.90. This indicates that DYN is financially healthy and has little risk of bankruptcy at the moment.
  • DYN has a Altman-Z score of 6.90. This is in the better half of the industry: DYN outperforms 76.94% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that DYN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.15, DYN is not doing good in the industry: 65.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 6.9
ROIC/WACCN/A
WACCN/A
DYN Yearly LT Debt VS Equity VS FCFDYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • DYN has a Current Ratio of 22.25. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of DYN (22.25) is better than 95.93% of its industry peers.
  • DYN has a Quick Ratio of 22.25. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 22.25, DYN belongs to the top of the industry, outperforming 95.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.25
Quick Ratio 22.25
DYN Yearly Current Assets VS Current LiabilitesDYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DYN Growth Analysis

3.1 Past

  • The earnings per share for DYN have decreased by -5.67% in the last year.
EPS 1Y (TTM)-5.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • DYN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.13% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.57%
EPS Next 2Y7.99%
EPS Next 3Y9.98%
EPS Next 5Y23.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DYN Yearly Revenue VS EstimatesDYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
DYN Yearly EPS VS EstimatesDYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. DYN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DYN. In the last year negative earnings were reported.
  • Also next year DYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYN Price Earnings VS Forward Price EarningsDYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYN Per share dataDYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.99%
EPS Next 3Y9.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DYN Dividend Analysis

5.1 Amount

  • DYN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DYN Fundamentals: All Metrics, Ratios and Statistics

DYNE THERAPEUTICS INC

NASDAQ:DYN (4/13/2026, 8:21:58 PM)

After market: 19.2 +0.2 (+1.05%)

19

+0.32 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)04-30
Inst Owners109.68%
Inst Owner Change0%
Ins Owners0.45%
Ins Owner Change2.09%
Market Cap3.14B
Revenue(TTM)N/A
Net Income(TTM)-446.21M
Analysts84
Price Target40.73 (114.37%)
Short Float %12.33%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.2%
Min EPS beat(2)2.28%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)-1.61%
Min EPS beat(4)-18.24%
Max EPS beat(4)10.13%
EPS beat(8)4
Avg EPS beat(8)-3.42%
EPS beat(12)4
Avg EPS beat(12)-7.98%
EPS beat(16)7
Avg EPS beat(16)-4.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.8%
PT rev (3m)1.9%
EPS NQ rev (1m)0.39%
EPS NQ rev (3m)4.03%
EPS NY rev (1m)9.33%
EPS NY rev (3m)10.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB 3.23
EV/EBITDA N/A
EPS(TTM)-3.54
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-2.57
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0
BVpS5.89
TBVpS5.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.59%
ROE -45.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.48%
ROA(5y)-63.28%
ROE(3y)-118.25%
ROE(5y)-92.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1010.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.25
Quick Ratio 22.25
Altman-Z 6.9
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)398.78%
Cap/Depr(5y)342.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
EPS Next Y15.57%
EPS Next 2Y7.99%
EPS Next 3Y9.98%
EPS Next 5Y23.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.19%
EBIT Next 3Y-1.02%
EBIT Next 5YN/A
FCF growth 1Y-43.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.91%
OCF growth 3YN/A
OCF growth 5YN/A

DYNE THERAPEUTICS INC / DYN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DYNE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to DYN.


Can you provide the valuation status for DYNE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DYNE THERAPEUTICS INC (DYN). This can be considered as Overvalued.


How profitable is DYNE THERAPEUTICS INC (DYN) stock?

DYNE THERAPEUTICS INC (DYN) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for DYN stock?

The Earnings per Share (EPS) of DYNE THERAPEUTICS INC (DYN) is expected to grow by 15.57% in the next year.